<DOC>
	<DOCNO>NCT00723983</DOCNO>
	<brief_summary>To compare pharmacokinetics NP101 currently approve oral formulation Imitrex® ( 50 mg ) migraine subject acute migraine attack non-migraine period .</brief_summary>
	<brief_title>Phase I , Open Label , Single-Dose , Four Way Crossover Study Compare PK NP101 With Oral Imitrex® ( 50mg ) Migraine Subjects During Acute Migraine Attack During Non-Migraine Period</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Sumatriptan</mesh_term>
	<criteria>Adult male female subject , age 18 65 year . Subjects diagnosis migraine headache , without aura , define ICHDII , diagnosis make age 50 . The majority subject 's headache migraine attack moderate severe intensity . Subject history regularly occur migraine , accompany nausea vomit . Subject least one year history migraine base upon subject testimony . Subject judge good health , base upon result medical history , physical examination , vital sign , ECG laboratory profile . Subjects must voluntarily sign date Informed Consent agreement approve IRB . Subject must negative drug screen rescreen . Female subject childbearing potential must negative pregnancy test Screening ReScreening . Subject two acceptable patch application site . Subject plan start stop , change treatment ( include dose change ) medication within one month prior subject screen date end study . Subject le 2 migraine per month subject 15 headache days/month 3 month prior ot screen . Subject suspect confirmed cardiovascular disease contraindicates study participation . Subject history epilepsy condition associate low seizure threshold . Subject Raynaud 's disease . Subject hemiplegic basilar migraine . Subject current diagnosis major depressive disorder . Subject take nontriptan serotonergic drug include SSRI 's , SNRI , TCAs MAOI 's preparation contain St. John 's Wort within month prior screen and/or plan start medication study End Study Visit . Subject unwilling discontinue use PD5 inhibitor ( eg . Viagra , Levitra , Cialis ) screen End Study Visit . Subject history significant allergy hypersensitivity component NP101 study patch . Subject generalized skin irritation disease include eczema , psoriasis , melanoma , acne contact dermatitis . Subject positive test result hepatitis B , hepatitis C know HIV positive . Subjects moderate severe hepatic dysfunction define SGOT/AST SGPT/ALT ≥ 2 time upper limit normal range , alkaline phosphatase total bilirubin ≥ 1.5 time upper limit normal range opinion investigator , subject 's history , physical examination laboratory test suggest hepatic dysfunction . Female subject pregnant , breast feeding , childbearing potential , use unwilling use effective form contraception study period 30 day follow final dosing . Subjects know history tolerability issue sumatriptan . Subject consider investigator NuPathe unsuitable candidate study . Subject history ( within 1 year ) current evidence drug alcohol abuse dependence . Subject participate clinical study within 30 day Screening plan participate another clinical study . Subject clinically significant abnormal lab , vital sign ECG Subject electrically sensitive implantable electronic device .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>